GT Biopharma Inc GTBP

$5.41 -1.90 (-25.99%)

Valuation

Market cap
13,789,000
Revenue TTM
$0
Net income TTM
$-28,350,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
169,831
Avg volume
67,071
Day's range
$5.31 – $6.90
Shares out
2,061,000
Stochastic %K
89%
Beta
0.86
Analysts
Sell
Price target
$75.00

Price

Company profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose...

Show more

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
415 919 4040
Website
https://www.gtbiopharma.com
Address
315 Montgomery Street, 10th Floor, San Francisco, United States

Latest news

Stocktwits

Arcides Oct 21, 7:30 PM
$GTBP most bios are pump and dump...4.91 to 11.98 back to 5.42
0 replies
chicharrotrading Oct 21, 11:47 AM
$GFAI $GTBP 🔥 today's watchlist — 1 micro/nano-cap + 1 micro/nano-floater covered below. $GFAI (#15) 🚀 strong momentum, ⚠️ elevated risk | Industrials/Security & Protection Services ($6.9M) 🔦 Chart flags a recent MACD/Signal crossover — 🏭 Global trade volumes Infrastructure spending Manufacturing PMI trends — 🌍 Trade policy Export controls Currency fluctuations Regional stability — 📰 Guardforce AI Reports Interim Financial Results for the First Half of 2026 (GlobeNewswire) — 🟡 External conditions: NEUTRAL $GTBP (#2) 🚀 strong momentum, ⚠️ elevated risk | Healthcare/Biotechnology ($15.1M) — Float 1.7M sh shares 🔦 Chart flags a recent cup & handle pattern — 🏭 FDA decision cycles Patent-cliff timing Health-policy debates — 🌍 National regulatory developments Policy headline sensitivity — 📰 With $31.2M left to sell, GT Biopharma (GTBP) has made its first equity sale. (Stock Titan) — 🟡 External conditions: NEUTRAL
0 replies
MadMaverick Oct 19, 2:52 PM
$GTBP gained ~15-20% last week... and I'm still watching. Why? • 2 Phase 1 trials enrolling patients • FDA cleared expansion into multiple myeloma • Novel NK-cell immunotherapy platform • Cash runway into Q3 2027 Sometimes the first move gets attention. The next move comes when more investors start digging into the story. Worth keeping on the watchlist for more upside! Communicated Disclaimer: https://stockresearchtoday.com/gtbp-2/ $WORX $YMAT $IRON
0 replies
Fractions1 Oct 14, 8:01 PM
$GTBP Looks like a very competitive field vs. IBRX...almost as though one spawned tother? js...glta
1 replies
MadMaverick Oct 14, 1:23 PM
WHAT MAKES $GTBP STAND OUT FROM THE REST?! $GTBP makes a drug that takes your body's natural cancer-fighting cells, sticks them directly onto the tumor, and keeps them switched on — no complicated cell transplant needed. Also they have Two Phase 1 trials are enrolling patients right now, and the FDA just cleared them to expand into multiple myeloma — with about $11M in cash to fund the work into Q3 2027. Communicated Disclaimer - stockresearchtoday.com/gtbp-2/ $LQDA $AEHL $NIVF $NCPL
0 replies
FonsieTrader Oct 13, 7:30 PM
$GTBP pulled back to the breakout zone today on relatively low volume after rejecting the upper trendline. Price closed near $6.36, right back into the prior support area of the descending triangle. This looks like a healthy retest rather than a breakdown so far. Good opportunity here for the coming days if volume starts picking up again. Don’t sleep on this one. Disclaimer: https://www.thetitanmedia.com/disclaimer
0 replies
FonsieTrader Oct 13, 2:30 PM
The way micro floats are running wild, I wouldn’t be surprised if $GTBP starts catching attention at any moment. 1.7M float and 14% short float are exactly what the market loves right now. Combined with a strong chart and solid catalysts, this looks like a real gem. Disclaimer: https://www.thetitanmedia.com/disclaimer/
0 replies
FonsieTrader Oct 13, 1:59 PM
$GTBP Pushing higher today on rising volume, testing the upper boundary of the descending triangle. Price hit $7.50 intraday and is holding gains near $7.00 as volume expands. A high-volume close above $7.50 would break the triangle to the upside and open a path toward $7.80–$8.50. Support sits at $6.80–$7.00. Early strength with volume confirmation still needed into the close. Disclaimer: https://www.thetitanmedia.com/disclaimer/
0 replies